HULUWA(SH:605199) Zheng Quan Zhi Xing·2025-08-29 18:30Core Viewpoint - The report indicates a significant decline in the financial performance of Hainan Huluwa Pharmaceutical Group Co., Ltd. for the first half of 2025, with substantial decreases in revenue and profit compared to the previous year [1][5]. Financial Summary - Total assets at the end of the reporting period amounted to CNY 2,913.61 million, a decrease of 1.72% from the previous year [1]. - Operating revenue for the period was CNY 507.67 million, representing a decline of 42.89% compared to CNY 888.95 million in the same period last year [1]. - Total profit for the period was CNY 8.18 million, down 83.71% from CNY 50.20 million in the previous year [1]. - The net profit attributable to shareholders was CNY -18.78 million, compared to a profit of CNY 4.53 million in the same period last year [1]. - The weighted average return on net assets decreased by 3.62 percentage points [1]. Shareholder Information - The largest shareholder, Hainan Huluwa Investment Development Co., Ltd., holds 41.76% of the shares, with 167.08 million shares pledged [2]. - Other significant shareholders include Zhejiang Fuwang Juder Health Development Co., Ltd. with 14.38% and Hangzhou Zhongjia Rui Management Partnership with 6.88% [2]. Important Matters - The company faced a risk warning due to a negative internal control audit report issued by the accounting firm, which led to the implementation of risk warnings on April 30, 2025 [3][5]. - In response to the audit findings, the company has initiated several corrective measures, including the establishment of a special rectification team led by the chairman to conduct comprehensive self-inspections [6]. - The company is enhancing its internal control management and compliance awareness through various initiatives, including risk assessments of new contracts and improved communication with external auditors [6].